Scheme for Strengthening of Medical Device Industry (SMDI) - Marginal Investment Scheme for Reducing Import Dependence (MISRID)
By Department of Pharmaceuticals
ClosedUp to ₹10CrNo equity taken
Loading...
By Department of Pharmaceuticals
Check your eligibility
Create a free account and we'll tell you whether your startup qualifies for this grant.
See if you're eligible
Full eligibility criteria — entity type, stage, sector, founder profile and registration requirements — plus your fit for this program. Create a free account to view.
The Department of Pharmaceuticals is a department under the Ministry of Chemicals & Fertilizers, Government of India. Created on July 1, 2008, the department was established to provide greater focus for the growth of India's high-potential pharmaceutical industry, one of the…
Learn more
Selection Process
The selection process for the SMDI-MISRID scheme involves a multi-stage evaluation designed to identify projects with the highest potential to meet the scheme's objectives. Applications will first undergo a Project Management Agency (PMA) appraisal to assess their completeness and adherence to basic criteria. Following this, a Technical Committee will review the technical feasibility, innovation, and strategic importance of the proposed manufacturing projects. Finally, the Scheme Steering Committee will provide the ultimate approval, ensuring that selected projects align with the overarching goals of strengthening the medical device industry and reducing import dependence.
Submit Application
Applicants submit their detailed project proposals and required documents online via the SMDI portal.
You
Four steps from draft to disbursement — one action each.
Submit on the official portal
Use the official application link and verify all details before final submission.
Follow up
Reach out 5–7 days after submitting to confirm receipt and ask about the review timeline.
Data on this page is compiled from official program and provider references.
The primary objective is to promote domestic production of key components, raw materials, and accessories used in medical device manufacturing, including in-vitro diagnostic devices, to reduce India's dependence on imports.
Eligible applicants include Central/State Government Organizations, Companies/LLPs registered in India, and Special Purpose Vehicles (SPVs) registered under the Companies Act or Societies Registration Act. This covers manufacturers of medical devices, IVDs, critical raw materials, and importers intending to shift to manufacturing.
The maximum capital subsidy is ₹10 Crore, disbursed on a reimbursement basis. The actual percentage (20%, 15%, or 10%) depends on the company's annual turnover, with smaller companies receiving a higher percentage of their investment as subsidy.
Quick Answer
A capital subsidy scheme under SMDI to promote domestic manufacturing of key medical device components and raw materials, reducing import dependency.
The Scheme for Strengthening of Medical Device Industry (SMDI) is a critical initiative by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, aimed at bolstering India's self-reliance in the medical device sector. Within this broader scheme, the Marginal Investment Scheme for Reducing Import Dependence (MISRID) specifically addresses the urgent need to localize the production of vital components, raw materials, and accessories essential for manufacturing medical devices, including in-vitro diagnostics (IVDs). India's medical device industry has historically relied heavily on imports for critical inputs, which poses significant supply chain risks and increases overall production costs. This scheme seeks to mitigate these dependencies by providing financial incentives to encourage domestic companies to invest in manufacturing these crucial items.
The objective is to create a robust indigenous ecosystem for medical device manufacturing, thereby enhancing India's capacity to produce high-quality, affordable medical devices. By supporting local production of key components like sensors, embedded systems, optical filters, electrodes, and medical-grade materials, SMDI-MISRID aims to foster innovation, create employment opportunities, and establish India as a global hub for medical device manufacturing. This strategic push is aligned with the 'Make in India' vision and contributes significantly to public health by ensuring the availability of essential medical devices within the country, especially during times of global health crises.
What You Get
Eligible activities include the manufacturing of key components, raw materials, and accessories for medical devices and IVDs. This covers items such as sensors, embedded systems, optical filters, electrodes, antigens/antibodies, polymer tubing, metal tubing, and medical-grade packaging materials.
Yes, as the incentive is a capital subsidy on a reimbursement basis, it implies that the applicant must make the initial investment, and a percentage of that investment will be reimbursed, requiring co-financing from the applicant.
Projects approved under the scheme are expected to be completed within two years from the date of final approval. A one-year extension may be granted under specific circumstances.
Replit Developer Credits — up to 50% off
Replit Core for 1 year. Official price ₹20,736 — SGI price ₹10,368. Leave your name and number and we call within one working day to complete payment.
Manus AI Credits — up to 50% off
Manus Pro for 1 year. Official price ₹19,584 — SGI price ₹9,792. Leave your name and number and we call within one working day to complete payment.
Notion SaaS Credits — up to ₹5L
Rs. 5 Lakhs+ in Notion workspace credits — databases, wikis, project management, and team docs — for new users with a work email.
Applications for this round closed on 24 July 2026. The organiser has not published a selection list that we can verify yet.
Selections for this programme are announced by Department of Pharmaceuticals. Official links are listed under Sources below.
We update this page when results are published, and when the next round opens.
